<DOC>
	<DOC>NCT00232037</DOC>
	<brief_summary>This study is being done to evaluate the long-term safety of tegaserod in women with symptoms of dyspepsia who have completed the core study. Tegaserod will be evaluated at 6 mg twice daily.</brief_summary>
	<brief_title>Extension Study to Assess the Long-Term Safety of Tegaserod in Women With Symptoms of Dyspepsia</brief_title>
	<detailed_description />
	<mesh_term>Dyspepsia</mesh_term>
	<mesh_term>Tegaserod</mesh_term>
	<criteria>Female, 18 years and older Fulfilled eligibility criteria in CHTF919D2301 (double blind study) and successfully completed the doubleblind study Early discontinuation from the doubleblind study Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>Dyspepsia, gastrointestinal, tegaserod</keyword>
</DOC>